Saturday, May 08th

Last update:05:44:44 AM IST

Recent Posts:
Homearrow News and Events Year 2011 India Rejects Abbot Labs HIV Drug Patent

India Rejects Abbot Labs HIV Drug Patent

Times of India
04 January 2011

India has rejected a drug patent application of a US multi–national pharma company, paving way for easy access to an important life–saving medication for HIV patients across the globe. The decision to reject the patent application on the important combination drug, Lopinavir/Ritonavir filed by Abbot Laboratories was given by the Indian patent office here during the weekend and it is a major victory to millions of HIV–positive patients around the globe, according to NGOs working with affected patients.

The Indian patent office has put a halt to the multi–national Abbott Laboratories patenting and said it was not an invention. "India, the world's leading supplier of affordable medicines, can now supply this drug to patients across the globe who are desperately waiting for treatment.

This combination drug is considered to be the frontline of defense for HIV positive patients who have failed to stay healthy with the first round of medicines available currently," Tahir M Amin, Director of Initiative for Medicines, Access & Knowledge (I–MAK), one of those who initiated legal action against the US company said on Monday.

"This ground–breaking victory for patients sets an important precedent to stop pharmaceutical companies from gaming the patent system, marking a new era of hope for millions of HIV people across the world," Amin said. IMAK was one of the opponents from US and others were Indian pharma companies like Cipla (Mumbai), Matrix Laboratories (Secunderabad) and Okasa Pharmaceuticals (Mumbai).

Disclaimer: The news story on this page is the copyright of the cited publication. This has been reproduced here for visitors to review, comment on and discuss. This is in keeping with the principle of ‘Fair dealing’ or ‘Fair use’. Visitors may click on the publication name, in the news story, to visit the original article as it appears on the publication’s website.




Know Your Rights!

Link to Aarogya

aarogya logo


This is YOUR sites, so if you have suggestions or feedback on how we can improve it for you, please let us know! We do our best to keep up!

Make a Suggestion